NASDAQ:CLVS - Clovis Oncology Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$47.87 +0.83 (+1.76 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$47.04
Today's Range$46.65 - $48.32
52-Week Range$41.31 - $99.45
Volume492,016 shs
Average Volume1.23 million shs
Market Capitalization$2.44 billion
P/E Ratio-9.38
Dividend YieldN/A
Beta1.37
Clovis Oncology logoClovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Receive CLVS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CLVS
CUSIP18946410
Phone303-625-5000

Debt

Debt-to-Equity Ratio0.92
Current Ratio6.55
Quick Ratio5.74

Price-To-Earnings

Trailing P/E Ratio-9.38
Forward P/E Ratio-8.98
P/E GrowthN/A

Sales & Book Value

Annual Sales$55.51 million
Price / Sales45.32
Cash FlowN/A
Price / CashN/A
Book Value$7.50 per share
Price / Book6.38

Profitability

EPS (Most Recent Fiscal Year)($5.12)
Net Income$-346,390,000.00
Net Margins-545.80%
Return on Equity-79.02%
Return on Assets-33.90%

Miscellaneous

Employees360
Outstanding Shares52,550,000
Market Cap$2,439.85

Clovis Oncology (NASDAQ:CLVS) Frequently Asked Questions

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.36) by $0.18. The biopharmaceutical company had revenue of $18.50 million for the quarter, compared to the consensus estimate of $18.34 million. Clovis Oncology had a negative return on equity of 79.02% and a negative net margin of 545.80%. The business's revenue was up 164.3% on a year-over-year basis. During the same period last year, the company posted ($1.33) EPS. View Clovis Oncology's Earnings History.

When is Clovis Oncology's next earnings date?

Clovis Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Clovis Oncology.

What price target have analysts set for CLVS?

13 analysts have issued 1 year price targets for Clovis Oncology's stock. Their predictions range from $55.52 to $110.00. On average, they anticipate Clovis Oncology's share price to reach $83.0578 in the next twelve months. This suggests a possible upside of 73.5% from the stock's current price. View Analyst Ratings for Clovis Oncology.

What is the consensus analysts' recommendation for Clovis Oncology?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

What are Wall Street analysts saying about Clovis Oncology stock?

Here are some recent quotes from research analysts about Clovis Oncology stock:
  • 1. According to Zacks Investment Research, "Clovis’ Rubraca is progressing well and registering sales growth. Nonetheless, Rubraca has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, Clovis received approval for the label expansion in second-line maintenance setting in the United States, irrespective of BRCA-mutation, and as monotherapy in Europe. Several studies on Rubraca, targeting different types of ovarian cancer patients, are currently underway. The company has stopped development of rociletinib upon receiving a CRL and lucitanib on negative results. Any further setback will adversely affect the company’s prospects. Moreover, with just one approved product in the portfolio, Clovis is heavily dependent on Rubraca for growth, which concerns us. Meanwhile, Rubraca is set to face intense competition from currently marketed PARP inhibitors. Clovis’ shares have underperformed the industry so far this year." (7/10/2018)
  • 2. Cann analysts commented, "We believe the current status of the PARP inhibitor market is resulting in less predictable physician adoption than is typical in oncology settings. As a result, we are adjusting our Rubraca sales outlook for 2018-2022. Our outlook for Clovis Oncology is being adjusted to account for changes to our revenue estimates for 2018-2022, as a result of changes to our outlook for Rubraca. We are decreasing our Q2 2018 estimated Rubraca sales to $23.2 million from $44.8 million, and our 2018 estimated Rubraca sales by 27.2% to $126.0 million from our prior estimate of $173.0 million. We are reducing 2019 estimated Rubraca sales by 24.6% to $292.1 million from $387.6 million. We are making modest adjustments to 2020-2022E." (6/11/2018)

Who are some of Clovis Oncology's key competitors?

Who are Clovis Oncology's key executives?

Clovis Oncology's management team includes the folowing people:
  • Mr. Patrick J. Mahaffy MA, Co-Founder, Chief Exec. Officer, Pres and Exec. Director (Age 55)
  • Dr. Gillian C. Ivers-Read BSc, Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations (Age 64)
  • Mr. Daniel W. Muehl CPA, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 54)
  • Dr. Lindsey Rolfe BSc, MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance (Age 50)
  • Mr. Corwin Dale Hooks, Chief Commercial Officer and Sr. VP (Age 51)

Has Clovis Oncology been receiving favorable news coverage?

Press coverage about CLVS stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Clovis Oncology earned a media sentiment score of 0.15 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 45.62 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by many different of institutional and retail investors. Top institutional investors include Fred Alger Management Inc. (0.33%), Creative Planning (0.15%), Fisher Asset Management LLC (0.11%), Conservest Capital Advisors Inc. (0.04%), Bank of Montreal Can (0.03%) and Essex Investment Management Co. LLC (0.03%). Company insiders that own Clovis Oncology stock include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Institutional Ownership Trends for Clovis Oncology.

Which institutional investors are selling Clovis Oncology stock?

CLVS stock was sold by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC and Creative Planning. Company insiders that have sold Clovis Oncology company stock in the last year include Gillian C Ivers-Read, James C Blair and Thorlef Spickschen. View Insider Buying and Selling for Clovis Oncology.

Which institutional investors are buying Clovis Oncology stock?

CLVS stock was acquired by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., Bank of Montreal Can, Fisher Asset Management LLC, Conservest Capital Advisors Inc. and Amalgamated Bank. View Insider Buying and Selling for Clovis Oncology.

How do I buy shares of Clovis Oncology?

Shares of CLVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $47.87.

How big of a company is Clovis Oncology?

Clovis Oncology has a market capitalization of $2.44 billion and generates $55.51 million in revenue each year. The biopharmaceutical company earns $-346,390,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Clovis Oncology employs 360 workers across the globe.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The biopharmaceutical company can be reached via phone at 303-625-5000 or via email at [email protected]


MarketBeat Community Rating for Clovis Oncology (NASDAQ CLVS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  395 (Vote Outperform)
Underperform Votes:  357 (Vote Underperform)
Total Votes:  752
MarketBeat's community ratings are surveys of what our community members think about Clovis Oncology and other stocks. Vote "Outperform" if you believe CLVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.